Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohn’s Disease

Princeton, NJ – May 15, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate […]

Soligenix Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate SGX942 for the Treatment of Oral Mucositis

Princeton, NJ – March 27, 2013 -Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today that the Food and Drug Administration (FDA) has completed its review and cleared the Investigational New Drug (IND) application for SGX942 for the treatment of oral mucositis resulting from radiation and/or chemotherapy treatment in […]

Soligenix Announces Significant Progress with ThermoVax™ Towards the Development of Heat Stable Vaccines

Research Conducted under $9.4 Million NIAID Cooperative Grant Princeton, NJ – March 19, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today key progress in the development of ThermoVax™, its proprietary vaccine thermostabilization technology. Several complementary preclinical studies have indicated the potential for high temperature stability for […]

Soligenix Submits BARDA Contract Proposal for Development of OrbeShield™ in GI ARS

Princeton, NJ – February 20, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today submission of a full contract proposal to the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures. This submission supports a potential multi-year, multi-million dollar […]

Soligenix to Present at 15th Annual BIO CEO & Investor Conference

Presentation to be Webcast Live, 3 PM EST, February 12th Princeton, NJ – February 12, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 2013 BIO CEO & Investor […]

FDA Grants Soligenix Fast Track Designation for OrbeShieldTM for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)

Princeton, NJ – January 29, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that its OrbeShield™ (oral beclomethasone 17,21-dipropionate or oral BDP) development program for the treatment of GI ARS has received “Fast Track” designation from the U.S. Food and Drug Administration (FDA). Soligenix has also […]

Soligenix Receives IND Clearance from FDA to Initiate Program Evaluating OrbeShield™ as a Therapy for Gastrointestinal Acute Radiation Syndrome

Princeton, NJ – January 4, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that the Food and Drug Administration (FDA) has completed its review and cleared the Investigational New Drug (IND) application for OrbeShield™ (oral beclomethasone 17,21-dipropionate or oral BDP) for the mitigation of morbidity and […]

Soligenix Regains North American and European CommercialRights to Oral BDP

Princeton, NJ – December 27, 2012 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, today announced that it has regained the North American and European commercial rights to oral BDP (beclomethasone 17.21-dipropionate) through an amendment of its Collaboration and Supply Agreement with Sigma-Tau Pharmaceuticals, Inc. Soligenix is now free […]

FDA Grants Soligenix Fast Track Designation for SGX203 for the Treatment of Pediatric Crohn’s Disease

Princeton, NJ – November 8, 2012 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that its program for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the induction treatment of mild-to-moderate pediatric Crohn’s disease has received “Fast Track” designation from the U.S. Food and Drug […]

Soligenix Announces Formation of Acute Radiation Syndrome Scientific Advisory Board

Princeton, NJ – October 3, 2012 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today the formation of a Scientific Advisory Board (SAB) to provide strategic guidance to the Company as it relates to the development of OrbeShield™ (oral beclomethasone dipropionate, or oral BDP) for the treatment of […]